Annex IV List of pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to be withdrawn from the list of products receiving duty-free treatment included in Annex 6 to Regulation (EC) No 1549/2006
United Kingdom
| ID No | CN code | CAS RN | Name |
|---|---|---|---|
| 677 | 2918 90 90 | 157283-68-6 | isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(E)-(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl}cyclopentyl]hept-5-enoate travoprost (INN) |
| 603 | 2924 29 95 | 112522-64-2 | 4-acetamido-2'-aminobenzanilide tacedinaline (INN) |
| 69 | 2924 29 95 | 166518-60-1 | N-[(2,6-diisopropylphenoxy)sulfonyl]-2-(2,4,6-triisopropylphenyl)acetamide avasimibe (INN) |
| 441 | 2928 00 90 | 53016-31-2 | 13-ethyl-17-alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one oxime norelgestromin (INN) |
| 833 | 2930 90 30 | 583-91-5 | 2-hydroxy-4-(methylthio)butyric acid desmeninol (INN) |
| 273 | 2932 99 70 | 114870-03-0 | methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1,4)-O-beta-D-glucopyranuronosyl-(1,4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1,4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1,4)-2-deoxy-2-(sulfoamino)-6-(hydrogen sulfate)-alpha-D-glucopyranoside, decasodium salt fondaparinux sodium (INN) |
| 627 | 2933 39 99 | 75970-99-9 | [1-(4-fluorobenzyl)-1H-benzimidazol-2-yl](4-piperidyl)amine tecastemizole (INN) |
| 159 | 2933 39 99 | 100643-71-8 | 8-chloro-11-(4-piperidylidene)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridine desloratadine (INN) |
| 549 | 2933 39 99 | 168273-06-1 | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidino-1H-pyrazole-3-carboxamide rimonabant (INN) |
| 380 | 2933 39 99 | 193275-84-2 | 4-{4-[(11R)-3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidinocarbonylmethyl}piperidine-1-carboxamide lonafarnib (INN) |
| 397 | 2933 49 90 | 146362-70-1 | 2-{[1-(7-chloro-4-quinolyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonylamino}adamantane-2-carboxylic acid meclinertant (INN) |
| 641 | 2933 59 95 | 147127-20-6 | (R)-[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methylphosphonic acid tenofovir (INN) |
| 205 | 2933 59 95 | 149950-60-7 | 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione emivirine (INN) |
| 511 | 2933 59 95 | 153537-73-6 | (S)-2-(4-{[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl](prop-2-ynyl)amino}-2-fluorobenzamido)-4-(1H-tetrazol-5-yl)butyric acid plevitrexed (INN) |
| 686 | 2934 99 90 | 112984-60-8 | (+-)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid ulifloxacin (INN) |
| 33 | 2934 99 90 | 145514-04-1 | (2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-ylmethanol amdoxovir (INN) |
| 513 | 2934 99 90 | 171228-49-2 | 4-[4-(4-{4-[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-ylmethyloxy]phenyl}piperazin-1-yl)phenyl]-1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,2,4-triazol-5(4H)-one posaconazole (INN) |
| 293 | 2934 99 90 | 184475-35-2 | (3-chloro-4-fluorophenyl)[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine gefitinib (INN) |
| 539 | 2935 00 90 | 150375-75-0 | N'-{(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-2,3-dihydro-1H-indol-2-ylcarbonyl}-L-prolinamide relcovaptan (INN) |
| 39 | 2935 00 90 | 161814-49-9 | (3S)-tetrahydrofuran-3-yl (1S,2R)-3-[(4-aminophenylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate amprenavir (INN) |
| 115 | 2935 00 90 | 169590-42-5 | 4-[5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide celecoxib (INN) |
| 654 | 2935 00 90 | 180200-68-4 | 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide tilmacoxib (INN) |
| 690 | 2935 00 90 | 181695-72-7 | 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide valdecoxib (INN) |
| 520 | 2935 00 90 | 192329-42-3 | (S)-N-hydroxy-2,2-dimethyl-4-[4-(4-pyridyloxy)phenylsulfonyl]-1,4-thiazinane-3-carboxamide prinomastat (INN) |
| 364 | 3002 10 95 | 193700-51-5 | SC-70935 leridistim (INN) |